

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5082504

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
VIVA BIOTECH (SHANGHAI) LTD.	02/27/2018
RECEIVING PARTY DATA	
Name:	AGIOS PHARMACEUTICALS, INC.
Street Address:	88 SIDNEY STREET
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15691408
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	request@slwip.com
Correspondent Name:	SCHWEGMAN LUNDBERG & WOESSNER P.A.
Address Line 1:	PO BOX 2938
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402-0938
ATTORNEY DOCKET NUMBER:	4634.002US1
NAME OF SUBMITTER:	KERRI WRIGHT
SIGNATURE:	/KERRI WRIGHT/
DATE SIGNED:	08/03/2018
Total Attachments: 4	
source=4634002US1_Viva_Agiossigned#page1.tif	
source=4634002US1_Viva_Agiossigned#page2.tif	
source=4634002US1_Viva_Agiossigned#page3.tif	
source=4634002US1_Viva_Agiossigned#page4.tif	

RECORDATION FORM COVER SHEET
PATENTS ONLY

Atty Ref/Docket No.: 4634.002US1

Patent and Trademark Office

To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Viva Biotech (Shanghai) Ltd.

Additional name(s) of conveying party(ies) attached?

Yes No

3. Nature of conveyance:

Assignment

Merger

Security Agreement Change of Name

Other

Execution Date: February 27, 2018

2. Name and address of receiving party(ies):

Name: Agios Pharmaceuticals, Inc.

Street Address: 88 Sidney Street

City: Cambridge State: MA Zip: 02139

Country: United States of America

Additional name(s) & address(es) attached? Yes No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

Serial No. 15/691,408

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Steven M. Reid

Address:

Swegman Lundberg & Woessner, P.A.
P.O. Box 2938
Minneapolis, Minnesota 55402

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$ 0.00

Enclosed

Authorized to be charged to deposit account 19-0743

8. Please charge any additional fees or credit any over payments to our Deposit Account No.: 19-0743


DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Steven M. Reid/Reg. No. 54,393

Name of Person Signing



Signature

August 2, 2018

Date

Total number of pages including cover sheet: 4

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
Mail Stop Assignment Recordation Services
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
REEL: 046552 FRAME: 0365

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, **Viva Biotech (Shanghai) Ltd., Suite 502, Building 8, 1403 Halei Road, ZhangJiang High-Tech Park, Pudong New Area 201203, Shanghai, P.R. China**, its successors, assigns and legal representatives (hereinafter the "Undersigned"), do hereby irrevocably and unconditionally:

CONVEY, ASSIGN AND TRANSFER to **Agios Pharmaceuticals, Inc.**, a Delaware corporation having a place of business at **88 Sidney Street, Cambridge, Massachusetts 02139, United States of America**, its successors, assigns and legal representatives (collectively hereinafter the "Assignee"), the Undersigned's entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for the United States Patent entitled **INHIBITORS OF CELLULAR METABOLIC PROCESSES**, filed **August 30, 2017**, and assigned U.S. Serial Number **15/691,408**, including:

the inventions disclosed in the above-identified application(s);

such application(s), and all divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other applications for a patent or patents which have been or shall be filed in the United States (including without limitation International Patent Application No. PCT/CN2016/097524, filed August 31, 2016 and entitled **INHIBITORS OF CELLULAR METABOLIC PROCESSES**; and U.S. Provisional Application No. 62/548,738, filed August 22, 2017, and entitled **INHIBITORS OF CELLULAR METABOLIC PROCESSES**), and in all foreign countries and jurisdictions based in whole or in part on any of the said inventions and improvements (including any application for a utility model, design registration(s), and inventor's certificate(s));

the right to claim priority to the above-identified application(s) in relation to subject matter based in whole or in part on the above-identified application(s) and any of the foregoing under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

the right to file in my name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventor's certificate(s) for said inventions and improvements in the United States and all foreign countries under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and

the right to all causes of action, remedies, and other enforcement rights related to the above-identified application(s), including without limitation the right to sue for past, present, or future infringement, misappropriation, or violation of any and all rights related to the above-identified application(s) and any of the foregoing, including the right to obtain and collect damages for past, present, or future infringement.

The Undersigned authorizes and requests the U.S. and foreign patent issuing authority to issue any and all United States and foreign patents (including any application for a utility model, design registrations, and inventor's certificate(s)) on the said inventions and improvements to the Assignee.

The Undersigned covenants, that when requested and at the reasonable expense of the Assignee, in order to carry out in good faith the intent and purpose of this Assignment, the Undersigned shall (1) execute all provisional, non-provisional, divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other patent applications for the inventions and improvements which are subject of the said application(s), as the Assignee may reasonably request to effectuate fully this Assignment; (2) execute all rightful oaths, declarations, assignments, powers of attorney and other papers for the inventions and improvements which are subject of the said application(s); (3) communicate to the Assignee all facts known to the Undersigned relating to the inventions and improvements which are subject of the said application(s), and the history thereof; (4) cooperate with the Assignee in any interference, reexamination, reissue, opposition, dispute, or litigation involving any of the applications or patents for the inventions and improvements which are subject of the said application(s); and (5) take such further actions as the Assignee shall reasonably consider necessary or desirable for vesting title to the said inventions and improvements in the Assignee, or for securing, maintaining and enforcing proper patent protection for the said inventions and improvements.

The Undersigned covenants, that should the execution date, filing date and/or Application Number be not entered or be incorrect at the time the Undersigned executed this document, the Undersigned hereby authorizes and requests an attorney of Assignee to insert the information or make the correction.

IN TESTIMONY WHEREOF, I have executed this document on the date indicated below.

By: **Viva Biotech (Shanghai) Ltd.**

Date 2/27/2018 Name: Ying Wu

Title: COO

Authorized Representative of Viva Biotech (Shanghai) Ltd.

Witnessed by:

(1) Qinbo Huang
Signature of Witness

Qinbo Huang
Print Witness Name

(2) Qian Gu
Signature of Witness

Qian Gu
Print Witness Name


2/27/2018
Date

Shanghai, China
Witness' City and Country of Residence

2/27/2018
Date

Shanghai, China
Witness' City and Country of Residence

ACCEPTED AND AGREED TO BY ASSIGNEE: **Agios Pharmaceuticals, Inc.:**

Signature: 

Date: March 5, 2018

Printed Name: Mia Wang, Ph.D., J.D.

Title: SVP, General Counsel